VRC 01 mRNA

Drug Profile

VRC 01 mRNA

Alternative Names: VRC01 mRNA-LNP

Latest Information Update: 06 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acuitas Therapeutics
  • Developer Acuitas Therapeutics; University of Pennsylvania
  • Class Antiretrovirals; Monoclonal antibodies; RNA
  • Mechanism of Action Gene transference; HIV antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV-1 infections

Most Recent Events

  • 06 Apr 2017 Preclinical trials in HIV-1 infections in Canada, USA (Injection) before April 2017
  • 02 Mar 2017 Preclinical data in HIV-1 infections released by Acuitas Therapeutics and the University of Pennsylvania
  • 01 Dec 2013 Arbutus Biopharma enters into a cross-license agreement with Acuitas Therapeutics for the former's lipid nanoparticle (LNP) technology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top